A Self‐Assembly Nano‐Prodrug for Combination Therapy in Triple‐Negative Breast Cancer Stem Cells
Small · 2023
DOI: 10.1002/smll.202301600 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2023. Verfasst von Chongzhi Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Guizhou University, Guiyang, 550025, P. R. China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Prodrugs, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Triple‐negative breast cancer (TNBC) displays a highly aggressive nature that originates from a small subpopulation of TNBC stem cells (TNBCSCs), and these TNBCSCs give rise to chemoresistance, tumor metastasis, and recurrence. Unfortunately, traditional chemotherapy eradicates normal TNBC cells but fails to kill quiescent TNBCSCs. To explore a new strategy for eradicating TNBCSCs, a disulfide‐mediated self‐assembly nano‐prodrug that can achieve the co‐delivery of ferroptosis drug, differentiation‐inducing agent, and chemotherapeutics for simultaneous TNBCSCs and TNBC treatment, is reported. In this nano‐prodrug, the disulfide bond not only induces self‐assembly behavior of different small molecular drug but also serves as a glutathione (GSH)‐responsive trigger in controlled drug release. More importantly, the differentiation‐inducing agent can transform TNBCSCs into normal TNBC cells, and this differentiation with chemotherapeutics provides an effective approach to indirectly eradicate TNBCSCs. In addition, ferroptosis therapy is essentially different from the apoptosis‐induced cell death of differentiation or chemotherapeutic, which causes cell death to both TNBCSCs and normal TNBC cells. In different TNBC mouse models, this nano‐prodrug significantly improves anti‐tumor efficacy and effectively inhibits the tumor metastasis. This all‐in‐one strategy enables controlled drug release and reduces stemness‐related drug resistance, enhancing the chemotherapeutic sensitivity in TNBC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Guizhou University, Guiyang, 550025, P. R. China.
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, P. R. China.
- State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, P. R. China.
ORCID-Profile: Bowen Li
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Wu, C., Zhang, F., Li, B., Li, Z., Xie, X., Huang, Y., Yao, Z., Chen, Y., Ping, Y., & Pan, W. (2023). A Self‐Assembly Nano‐Prodrug for Combination Therapy in Triple‐Negative Breast Cancer Stem Cells. Small. https://doi.org/10.1002/smll.202301600
Vancouver
Wu C, Zhang F, Li B, Li Z, Xie X, Huang Y, et al. A Self‐Assembly Nano‐Prodrug for Combination Therapy in Triple‐Negative Breast Cancer Stem Cells. Small. 2023. doi:10.1002/smll.202301600
BibTeX
@article{Wu2023,
author = {Wu, Chongzhi and Zhang, Fu and Li, Bowen and Li, Zhiyao and Xie, Xin and Huang, Yong and Yao, Zhuo and Chen, Yuan and Ping, Yuan and Pan, Weidong},
title = {A Self‐Assembly Nano‐Prodrug for Combination Therapy in Triple‐Negative Breast Cancer Stem Cells},
journal = {Small},
year = {2023},
doi = {10.1002/smll.202301600}
}
EUVIMED